Ketorolac
- Generic Name
- Ketorolac
- Brand Names
- Acular, Acuvail, Omidria, Readysharp Anesthetics Plus Ketorolac, Sprix, Toradol, Toronova Suik
- Drug Type
- Small Molecule
- Chemical Formula
- C15H13NO3
- CAS Number
- 74103-06-3
- Unique Ingredient Identifier
- YZI5105V0L
- Background
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.
...
- Indication
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and has antipyretic, analgesic and anti-inflammatory properties. It is indicated for short term management of acute pain that requires the calibre of pain management offered by opioids. Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft tissue pain, rheumatoid...
- Associated Conditions
- Acute Migraine, Eye Pain, Inflammation, Macular Edema, Cystoid, Ocular Itching, Pericarditis Acute, Pseudophakic Cystoid Macular Oedema, Severe Acute Pain, Acute, moderate Pain, Chronic aphakic cystoid macular edema, Intraoperative miosis, Postoperative ocular pain
- Associated Therapies
- -
Effect of Spinal Ketorolac After Acute Opioid Exposure
- Conditions
- Interventions
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 30
- Registration Number
- NCT00693160
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management
- Conditions
- Interventions
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Maimonides Medical Center
- Target Recruit Count
- 67
- Registration Number
- NCT00638508
- Locations
- 🇺🇸
Maimonides Medical Center, Brooklyn, New York, United States
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
- Conditions
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- University of South Alabama
- Target Recruit Count
- 83
- Registration Number
- NCT00634972
- Locations
- 🇺🇸
Division of Neonatology, Children's & Women's Hospital, University of South Alabama, Mobile, Alabama, United States
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%
- Conditions
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2009-03-19
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 166
- Registration Number
- NCT00595543
- Locations
- 🇺🇸
Soll Eye Associates, Philadelphia, Pennsylvania, United States
Topical 0.4% Ketorolac and Vitreoretinal Surgery
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 76
- Registration Number
- NCT00576329
- Locations
- 🇺🇸
Emory Eye Clinic, Atlanta, Georgia, United States
Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Asker & Baerum Hospital
- Target Recruit Count
- 102
- Registration Number
- NCT00562627
- Locations
- 🇳🇴
Asker and Baerum Hospital, Rud, Norway
RCT on Ketorolac and Tramadol in Bone Fractures Pain of Child
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- IRCCS Burlo Garofolo
- Target Recruit Count
- 133
- Registration Number
- NCT00560443
- Locations
- 🇮🇹
IRCCS Burlo Garofolo, Trieste, Italy
Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2008-07-16
- Lead Sponsor
- Javelin Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT00548678
- Locations
- 🇺🇸
Comprehensive Phase One, Miramar, Florida, United States
A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2009-10-01
- Lead Sponsor
- Allergan
- Target Recruit Count
- 248
- Registration Number
- NCT00524264
Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- Florida Eye Microsurgical Institute
- Target Recruit Count
- 42
- Registration Number
- NCT00520260
- Locations
- 🇺🇸
Florida Eye Microsurgical Institute, Boynton Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.